Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Precision Perspectives: Navigating Advancements in HR+ / HER2 Negative Breast Cancer Care : Episode 13
Opinion
Video
Exploring Therapeutic Alternatives to CDK4/6 Inhibitors in Metastatic Breast Cancer
Heather Moore, BCOP, CPP, PharmD, discusses switching from CDK4/6 inhibitors to later lines of therapy, typically due to toxicities, to alleviate symptoms. She emphasizes the goal of finding a new therapy rather than abandoning treatment altogether, and notes that targeted therapy may be necessary in cases of disease progression.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Videos
Related Content
